Celgene (NASDAQ:CELG)

biotech word cloud

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the most recent settlement date, September 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »
Test tubes

RBC Says These 4 Top Biotechs Could Have Big Upside Potential

We have talked in detail about how the political rhetoric has weighed upon the biotech industry. Toss in some scrutiny of pricing over a widely used product, and you have ...
Read Full Story »
blood cells

Agios Files for Secondary Offering

Agios Pharmaceuticals Inc. (NASDAQ: AGIO) has filed with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering. The company intends to offer up to $150 million of its ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

Companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside. In fact, a cure or incredible new breakthrough in cancer ...
Read Full Story »
clinical trials

4 Key BioPharma Movers in the Past Week

A few biotech companies made impressive runs over the course of this past week. In the past 52 weeks, biotech and pharmaceutical stocks have been absolutely crushed. However the year ...
Read Full Story »
Female patient on gurney

Did Agios Just Speed Up Its Business Plan by 2 Years?

Celgene Corp. (NASDAQ: CELG) is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals Inc. (NASDAQ: AGIO) significantly higher. In a surprise move, Celgene is ...
Read Full Story »
biotech word cloud

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the August 15 settlement date. Companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big ...
Read Full Story »
money

How Much Medivation Can Really Fetch in a Buyout

Medivation Inc. (NASDAQ: MDVN) has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, ...
Read Full Story »
Test tubes

Top Biotechs Are Among Jefferies Growth Stock Favorites

One thing that has stretched multiples in the S&P 500 this year to a pricey 17 times earnings is that many people have chased a few stocks in the index ...
Read Full Story »
automatic inspection machine

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 29 settlement date. Companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big ...
Read Full Story »
money

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

The Nasdaq Biotechnology Index has underperformed the broader market for some time. This year the index is still down about 13%, versus the 6% rise for the S&P 500. We ...
Read Full Story »
thumbs up and down

Top Analyst Upgrades and Downgrades: Apollo Global, ADM, Celgene, Total, Whole Foods, Targa Resources and More

Stocks were indicated higher on Thursday after the Bank of England cut interest rates for the first time in seven years and engaged in more aggressive quantitative easing than expected. ...
Read Full Story »
buy now

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

We have talked about it for months here at 24/7 Wall St., and now many on Wall Street are talking about it as well. The selling in biotech, much of ...
Read Full Story »
clinical trials

How Celgene Won With This Earnings Report

Celgene Corp. (NASDAQ: CELG) reported its second-quarter financial results before the markets opened on Thursday. This company has an outstanding partnered pipeline, which most think is low risk and has ...
Read Full Story »
Test tubes

JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now

We have noted recently that large pharmaceuticals and biotech have been hammered, and now may be offering outstanding total return potential. While the larger pharmaceutical stocks have done better recently, the ...
Read Full Story »